European Medicines Agency validates marketing authorisation application for retifanlimab for the treatment of squamous cell anal carcinoma (SCAC)
The application for approval of the intravenous PD-1 inhibitor is based on data from the Phase II POD1UM-202 trial of its use in previously treated patients with locally advanced or metastatic SCAC who have progressed on, or are intolerant of, standard platinum-based chemotherapy
Source:
Biospace Inc.